AbbVie
Pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 23 % | 3 % | (6 %) | 4 % | 8 % | 9 % | 7 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 29 % | 34 % | 33 % | 31 % | 47 % | 50 % | 51 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 21 % | 20 % | 9 % | 8 % | 17 % | 24 % | 26 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 13 % | 11 % | 14 % | 23 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
AbbVie Inc. is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines. The company operates in the healthcare sector, primarily targeting patients with serious health conditions. AbbVie's portfolio includes treatments for a wide range of diseases, including immunology, oncology, virology, and neuroscience. The company also has a significant presence in the aesthetics market, offering products for aesthetic treatments.
AbbVie's clients include healthcare providers, hospitals, and clinics, as well as patients who require specialized medications. The company operates in various markets around the world, with a strong presence in North America, Europe, and Latin America.
The business model of AbbVie revolves around extensive research and development (R&D) to create new and effective treatments. The company invests heavily in R&D, with a reported $50 billion investment to date, to ensure a steady pipeline of new products. AbbVie makes money by selling its pharmaceutical products to healthcare providers and directly to patients through prescriptions. Additionally, the company generates revenue from its aesthetic products, which are sold to dermatologists and plastic surgeons.
AbbVie's commitment to improving patient care is evident through its continuous efforts in R&D and its focus on addressing unmet medical needs. The company also emphasizes sustainability and responsibility, aiming for science-based targets to ensure long-term growth.
In summary, AbbVie is a leading biopharmaceutical company dedicated to developing innovative treatments for serious health conditions, serving healthcare providers and patients globally, and generating revenue through the sale of its pharmaceutical and aesthetic products.
Keywords: Biopharmaceutical, Immunology, Oncology, Virology, Neuroscience, Aesthetics, Healthcare, R&D, Patient Care, Sustainability.
Tech stack
